top of page
pairx faded5.png

Next Generation
Cancer Immunotherapies

About us

PairX Bio Pte. Ltd. is developing next generation cancer immunotherapies targeting shared tumour-associated antigens derived from aberrantly spliced proteins. The PairX platform is built upon a deep understanding of mRNA splicing biology, which when combined with our proprietary antigen and T cell validation methods yield simultaneous validation of tumour antigen-T cell pairs in multiple patient derived tumours.

The technology was developed at Duke-NUS Medical School in Prof David Epstein’s lab (Founder & CEO of Black Diamond Therapeutics, Inc). The company was incubated by EVX Ventures and spun out from Duke-NUS. The founding investors are EVX Ventures and Avendesora (an investment company represented by Jeffrey Lu and Dr. Timothy Lu).

About us
bottom of page